[Second-line Hycamtin in the treatment of lung cancer].
OBJECTIVE
To discuss the therapeutic effect and toxicity of second line Hycamtin for lung cancer patients.


METHODS
Ten of these 21 patients had been treated with operation. All these 21 patients received second line Hycamtin treatment; given at the dose of 1.2 mg/m(2) per day, four consecutive days as one cycle and 21 days as one course. A total of 1 - 4 courses were given according to the patient's tolerance. Four of these 21 patients also received combination of cisplatin.


RESULTS
Among the 13 un-operated patients, two patients showed CR, six showed PR, three SD and two PD, giving an effective rate of 62%. Among the 8 operated patients, seven showed SD but one developed distant metastasis. The 1-year survival rate was 88%.


RESULTS
leukopenia I-II degree 14 (66.7%), leukopenia III-IV degree 5 (23.8%), thrombocytopenia III-IV degree 1 (4.8%) and one patient died of high fever and neutocytopenia. Nausea 8 (38.1%), vomiting 3 (14.3%) and diarrhea 2 (9.5%) alopecia 4 (19.1%). Were the other side-effects.


CONCLUSIONS
Hycamtin is indicated for second line therapy for lung cancer giving tolerable toxicity.
Zhang
Yi
Y
Department of Thoracic Surgery, Beijing Thoracic Tumor Hospital, Beijing 101149, China.
Zhi
Xiu-yi
XY
Zhao
Li-qiang
LQ
Han
Ming
M
Yan
Dong-jie
DJ
Yu
Da-ping
DP
Ruan
Jun-zhong
JZ
Li
Fu-gen
FG
Liu
Zhi-dong
ZD
Yang
Sheng
S
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D019772:Topotecan / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D019772:Topotecan